Please let us know if you agree to all of these cookies..
We are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer.
F-star’s wholly owned pipeline generates first and best-in-class drug candidates that work with patients’ immune systems to stop tumors from evading the body’s defense mechanisms.
F-star’s proprietary tetravalent bispecific antibody format ensures focused, potent and safe activation of the patient’s immune system.
Our most advanced drug candidate completing a Phase 1 clinical trial with patients who have not had a durable response to current immunotherapies.